Theriva Biologics (NYSEAMERICAN:TOVX) Upgraded at Maxim Group

Theriva Biologics (NYSEAMERICAN:TOVX) was upgraded by equities researchers at Maxim Group from a “hold” rating to a “buy” rating in a report released on Tuesday,Benzinga reports. The brokerage currently has a $1.00 target price on the stock. Maxim Group’s price objective indicates a potential upside of 410.73% from the company’s previous close.

Theriva Biologics Stock Performance

Shares of NYSEAMERICAN TOVX traded up $0.01 during trading on Tuesday, reaching $0.20. The stock had a trading volume of 2,013,266 shares, compared to its average volume of 12,327,300. The company has a debt-to-equity ratio of 0.11, a quick ratio of 1.74 and a current ratio of 1.74. The stock has a market cap of $6.61 million, a PE ratio of -0.01 and a beta of 0.53. Theriva Biologics has a one year low of $0.16 and a one year high of $1.50. The firm’s 50 day moving average price is $0.19 and its two-hundred day moving average price is $0.26.

Theriva Biologics (NYSEAMERICAN:TOVX) last announced its quarterly earnings data on Thursday, March 12th. The company reported $1.30 earnings per share (EPS) for the quarter.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Theriva Biologics stock. Geode Capital Management LLC lifted its holdings in shares of Theriva Biologics, Inc. (NYSEAMERICAN:TOVX) by 651.8% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 212,087 shares of the company’s stock after buying an additional 183,878 shares during the period. Geode Capital Management LLC owned 0.63% of Theriva Biologics worth $45,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 6.17% of the company’s stock.

About Theriva Biologics

Theriva Biologics, Inc, a clinical-stage company, develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States. The company’s lead product candidate is VCN-01, a clinical stage oncolytic human adenovirus that is in a Phase 2 clinical study for the treatment of pancreatic cancer; a Phase 1 clinical study for the treatment of retinalblastoma; a Phase 1 clinical study for the treatment of head and neck squamous cell carcinoma; and a Phase 1 clinical study for the treatment of solid tumors.